用于胰腺癌的诊断生物标志物：最新进展。
Diagnostic biomarkers for pancreatic cancer: An update.
机构信息
Department of Surgery, University of Missouri, Columbia, MO 65212, United States.
Department of Veterinary Pathobiology, University of Missouri, Columbia, MO 65212, United States.
出版信息
World J Gastroenterol. 2021 Dec 7;27(45):7862-7865. doi: 10.3748/wjg.v27.i45.7862.
Abstract
Pancreatic ductal adenocarcinoma accounts for the primary type of pancreatic cancer (PC) with a 5-year survival rate of only about 10% in the United States. Early diagnosis will improve chances for curative treatment. To date, a broadly used serum marker for PC diagnosis is carbohydrate antigen 19-9, which is the only approved biomarker currently by the United States Food and Drug Administration. However, it has low specificity; therefore, development of novel biomarkers is urgently needed. Clinical trials are ongoing to evaluate candidate biomarkers for PC diagnosis, and the use of a multi-biomarker panel with current PC diagnostic biomarkers appears promising.
摘要
胰腺导管腺癌占美国原发性胰腺癌（PC）的主要类型，其 5 年生存率仅约为 10%。早期诊断将提高治愈治疗的机会。迄今为止，广泛用于 PC 诊断的血清标志物是癌抗原 19-9，这是美国食品和药物管理局目前唯一批准的生物标志物。然而，它的特异性较低；因此，迫切需要开发新的生物标志物。目前正在进行临床试验以评估 PC 诊断候选生物标志物，并且使用当前 PC 诊断生物标志物的多标志物组合似乎很有前途。
相似文献
1
Diagnostic biomarkers for pancreatic cancer: An update.
World J Gastroenterol. 2021 Dec 7;27(45):7862-7865. doi: 10.3748/wjg.v27.i45.7862.
2
Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive.
Cancer J. 2012 Nov-Dec;18(6):530-8. doi: 10.1097/PPO.0b013e31827654ea.
3
Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
Cancer Sci. 2018 Sep;109(9):2841-2851. doi: 10.1111/cas.13712. Epub 2018 Jul 24.
4
Potential biomarkers for early detection of pancreatic ductal adenocarcinoma.
Clin Transl Oncol. 2020 Dec;22(12):2170-2174. doi: 10.1007/s12094-020-02372-0. Epub 2020 May 23.
5
Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma.
J Gastroenterol. 2010;45(1):52-9. doi: 10.1007/s00535-009-0114-y. Epub 2009 Sep 30.
6
Identification of human complement factor B as a novel biomarker candidate for pancreatic ductal adenocarcinoma.
J Proteome Res. 2014 Nov 7;13(11):4878-88. doi: 10.1021/pr5002719. Epub 2014 Aug 8.
7
Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology.
PLoS One. 2016 Jan 25;11(1):e0147214. doi: 10.1371/journal.pone.0147214. eCollection 2016.
8
Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
Cancer Biomark. 2018 Feb 14;21(3):505-511. doi: 10.3233/CBM-170203.
9
Serum fibrinogen as a diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
Pancreatology. 2020 Oct;20(7):1465-1471. doi: 10.1016/j.pan.2020.06.010. Epub 2020 Jul 14.
10
Current and future biomarkers for pancreatic adenocarcinoma.
Tumour Biol. 2017 Jun;39(6):1010428317692231. doi: 10.1177/1010428317692231.
引用本文的文献
1
Clinical significance of risk factor analysis in pancreatic cancer by using supervised model of machine learning.
Front Med (Lausanne). 2025 May 26;12:1551926. doi: 10.3389/fmed.2025.1551926. eCollection 2025.
2
Personalized Medicine in Pancreatic Cancer: The Promise of Biomarkers and Molecular Targeting with Dr. Michael J. Pishvaian.
Cancers (Basel). 2024 Jun 26;16(13):2329. doi: 10.3390/cancers16132329.
3
Hypoxia-Challenged Pancreatic Adenocarcinoma Cell-Derived Exosomal circR3HCC1L Drives Tumor Growth Via Upregulating PKM2 Through Sequestering miR-873-5p.
Mol Biotechnol. 2025 Feb;67(2):762-777. doi: 10.1007/s12033-024-01091-z. Epub 2024 Mar 25.
4
Postbiotic butyrate: role and its effects for being a potential drug and biomarker to pancreatic cancer.
Arch Microbiol. 2024 Mar 13;206(4):156. doi: 10.1007/s00203-024-03914-8.
5
Nuclear overexpression of DNA damage-inducible transcript 4 (DDIT4) is associated with aggressive tumor behavior in patients with pancreatic tumors.
Sci Rep. 2023 Nov 8;13(1):19403. doi: 10.1038/s41598-023-46484-3.
6
A Novel HOXA10-Associated 5-Gene-Based Prognostic Signature for Stratification of Short-term Survivors of Pancreatic Ductal Adenocarcinoma.
Clin Cancer Res. 2023 Sep 15;29(18):3759-3770. doi: 10.1158/1078-0432.CCR-23-0825.
7
Clinical diagnosis and management of pancreatic cancer: Markers, molecular mechanisms, and treatment options.
World J Gastroenterol. 2022 Dec 28;28(48):6827-6845. doi: 10.3748/wjg.v28.i48.6827.
8
Exploration of Risk Factors for Pancreatic Cancer and Development of a Clinical High-Risk Group Rating Scale.
J Clin Med. 2023 Jan 2;12(1):358. doi: 10.3390/jcm12010358.
9
Identification of MYEOV-Associated Gene Network as a Potential Therapeutic Target in Pancreatic Cancer.
Cancers (Basel). 2022 Nov 4;14(21):5439. doi: 10.3390/cancers14215439.
10
Crosstalk between gut microbiota and COVID-19 impacts pancreatic cancer progression.
World J Gastrointest Oncol. 2022 Aug 15;14(8):1456-1468. doi: 10.4251/wjgo.v14.i8.1456.
本文引用的文献
1
Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket?
World J Gastroenterol. 2021 Jul 14;27(26):4045-4087. doi: 10.3748/wjg.v27.i26.4045.
2
A case of raised CA 19-9 in a patient with desmoplastic fibroblastoma of the upper limb.
Int Cancer Conf J. 2021 Apr 24;10(3):222-227. doi: 10.1007/s13691-021-00485-z. eCollection 2021 Jul.
3
The role of liver sinusoidal endothelial cells in cancer liver metastasis.
Am J Cancer Res. 2021 May 15;11(5):1845-1860. eCollection 2021.
4
Multi-biomarker panel prediction model for diagnosis of pancreatic cancer.
J Hepatobiliary Pancreat Sci. 2023 Jan;30(1):122-132. doi: 10.1002/jhbp.986. Epub 2021 Jun 2.
5
Serum Dickkopf-1 in Combined with CA 19-9 as a Biomarker of Intrahepatic Cholangiocarcinoma.
Cancers (Basel). 2021 Apr 12;13(8):1828. doi: 10.3390/cancers13081828.
6
Diagnostic model for pancreatic cancer using a multi-biomarker panel.
Ann Surg Treat Res. 2021 Mar;100(3):144-153. doi: 10.4174/astr.2021.100.3.144. Epub 2021 Feb 26.
7
Cancer Statistics, 2021.
CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.
8
MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases.
Gut. 2021 Apr;70(4):784-795. doi: 10.1136/gutjnl-2020-322526. Epub 2020 Oct 30.
9
The Behavior of MMP-2, MMP-7, MMP-9, and Their Inhibitors TIMP-1 and TIMP-2 in Adenoma-Colorectal Cancer Sequence.
Dig Dis. 2021;39(3):217-224. doi: 10.1159/000511765. Epub 2020 Sep 22.
10
Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer.
Int J Cancer. 2020 May 15;146(10):2913-2922. doi: 10.1002/ijc.32751. Epub 2019 Nov 11.
Zotero 插件